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given that HELP represents a last therapeutic option for these
patients. The annual budget impact was $1.0 and $61.0 million
(CAD) for HMZ and HTZ FH patients respectively. Costs were
halved with biweekly treatment. The cost per CHD death
avoided comparing HELP with Plasma Exchange (PE), current
treatment, and with no intervention in HTZ FH was estimated to
be $37.5 million and $18.7 million for weekly and biweekly
treatment respectively. Although HELP costs twice as much as
PE, it avoided 12 deaths versus PE and 22 deaths versus no
intervention over a 10-year period. CONCLUSION: There is
evidence of overall clinical beneﬁt of LDL apheresis for HMZ
and HTZ FH. The diffusion of LDL apheresis for refractory HTZ
FH should factor affordability and potential capital and human
resource constraints.
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OBJECTIVE: Point-of-Care (POC) devices that measure the
International Normalized Ratio (INR) may be associated with
enough measurement error to inﬂuence warfarin dosing deci-
sions. The purpose of this trial was to determine if there were
differences between any of ﬁve FDA-approved POC testing
devices in terms of the proportion of time patients spend in the
target INR range (TR). METHODS: In this longitudinal clinical
trial, patients were randomized to one of ﬁve POC devices that
measure the INR (International Normalized Ratio). Patients
were followed over time according to usual anticoagulation clinic
practice. Clinicians used measurements from the POC device to
make all clinical decisions, including warfarin dose changes. At
each visit, a venous blood sample was also collected to serve as
an accepted standard measure to calculate time in the target
range (TR). A Bayesian hierarchical model with a parametric
variance component for estimating coagulation times between
observed blood draws was used to estimate the mean proportion
of time each patient’s INR was within his or her TR. The analysis
assessed the probability that each device resulted in patients’ INR
values within the TR over time, as measured by the accepted
standard laboratory measure. RESULTS: A total of 287 patients
were enrolled, completed 3 visits, and were monitored for an
average of 87 days. There was signiﬁcant differences in the time
patients’ INR values were in the target range, based on POC
device: Coaguchek S (52.2%), Coaguchek ProDM (51.5%)
Hemochron Jr. (48.3%), ProTime (45.5%), and Rapidpoint
(41.2%). The posterior probabilities that the Coaguchek S and
Coaguchek ProDM were the superior devices were 0.58 and
0.31, respectively. CONCLUSION: Five FDA-approved POC
INR devices resulted in signiﬁcantly different time in the TR. This
suggests that there are clinically signiﬁcant differences amongst
FDA-approved devices. Measurement of clinical outcomes may
improve the regulatory approval process.
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OBJECTIVE: Evaluate treatment patterns and levels of blood
pressure (BP) and glycemic control in elderly patients with
comorbid hypertension and type 2 diabetes. METHODS: Retro-
spective review of 2 consecutive years (August 1, 2005–July 31,
2007) of medical claims, pharmacy claims, and medical charts
from a physician group, comprised of more than 200 physicians,
located in the Ohio Valley region. Patients 65 years-of-age and
older with an ICD-9 diagnosis code for both hypertension and
type 2 diabetes were identiﬁed for inclusion between August 1,
2005–July 31, 2006, and evaluated from August 1, 2006–July
31, 2007. Administrative claims databases were utilized to
analyze treatment patterns. Medical charts was reviewed to
conﬁrm diagnoses and collect clinical indicators of control,
including BP and hemoglobin A1C measurements. RESULTS:
This study included 505 patients with hypertension and type 2
diabetes. The mean age was 75.7 years, and 57% were females.
Approximately 35% (n = 177) achieved BP goal of <130/
80 mmHg, while 58% (n = 293) achieved glycemic control,
deﬁned as A1C <7%. Only 26% (n = 133) attained both goal BP
and A1C levels. The most prescribed antihypertensive and anti-
hyperglycemic classes were beta-blockers (50%) and sulfony-
lureas (44%), respectively. Forty-seven percent of the patients
were on an angiotensin converting enzyme inhibitor, and 14%
were on an angiotensin receptor blocker. Antihypertensive mono-
therapy was the least prevalent (21%) mode of therapy, followed
by therapy with two agents (29%), and >3 agents (50%). In
contrast, antthyperglycemic monotherapy was the most preva-
lent (55%) mode of therapy, followed by dual therapy (30%),
and >3 agents (15%). CONCLUSION: Elderly patients with
comorbid hypertension and type 2 diabetes did not achieve goal
BP, and over 40% did not achieve goal A1C. Further opportu-
nities to educate both health care providers and patients are
necessary in order to prevent complications associated with the
poor management of these two common conditions.
PCV78
INTERNATIONAL COMPARISON OF HEALTH CARE
RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY
SYNDROME PATIENTS IN 2007: RESULTS FROMTHE
ANTIPLATELETTREATMENT OBSERVATIONAL STUDY
(APTOR)
Bakhai A1, Iniguez A2, Ferrieres J3, Needs N4, Schmitt C4, Sartral M5,
Zeymer U6
1Barnet & Chase Farm NHS Trust, Barnet, UK, 2Hospital Meixoeiro,
Vigo, Spain, 3CHU Rangueil, 31059 Toulouse, France, 4Eli Lilly and
Company Ltd,Windlesham, Surrey, UK, 5Eli Lilly and Company Ltd,
Suregnes, Paris, France, 6Institute for MI Research, Ludwigshafen,
Germany
OBJECTIVE: To explore variation in practice and its impact on
QoL in management of acute coronary syndromes (ACS), the
commonest cardiac cause of hospital admission. METHODS: A
prospective, international, observational study recruited ACS
patients undergoing percutaneous coronary intervention (PCI),
January–August 2007, capturing practice patterns, resource use
and QoL. RESULTS: A total of 1525 ACS-PCI patients (Spain-
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538, UK-504, France-483), under 122 cardiologists, mean age 62
(SD 12), mean weight 80 kg (SD 15), 22% female were recruited
with co-morbidities of hypertension-53%, dyslipidemia-52%,
diabetes-20% and prior MI-23%. Index diagnosis was: non
ST-elevation ACS-62% and ST-elevation MI (STEMI)-38%.
Admission and discharge use of medications were: aspirin-36 &
95%, clopidogrel-21 & 94%, statins-37 & 84%, beta-
blockers-30 & 76% and ACE inhibitors/ARBs-34 & 67%. 2349
stents were used (DES-52%; France-33%, Spain-64%, UK-55%)
with 58% of patients receiving only one. A total of 51% of
patients were transferred at least once between study and another
hospital, France-54%, Spain-46%, UK-54%. Admission to PCI
at study hospital was: median 2 days (IQR 1–5 days) for non-ST
ACS patients, (65% 3 days or less; France-87%, Spain-72%,
UK-38%); and median 0 days (IQR 0–2 days) for STEMI
patients, (73% 1 day or less; France-82%, Spain-74%,
UK-58%). Total stay was median 6 days (IQR 4–9) for both
cohorts. QoL at hospital discharge using EQ-5D health state
index was: median 0.85 (IQR 0.71–1.00) with 1 representing
perfect health, (France-0.85 (0.73–1.00), Spain-0.85 (0.73–
1.00), UK-0.81 (0.68–1.00)). CONCLUSION: These data indi-
cate geographic and case mix variation in management of ACS
patients, including use of DES, but with uniform early QoL
ﬁndings. Use of pharmacotherapies is high. Long term QoL will
assess the impact of variations, but these early ﬁndings are useful
benchmarks to guide service provision, focus treatment guide-
lines and validate clinical trials.
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OBJECTIVE: To assess trends in utilization of stroke-related
outpatient physician services by physician specialty over the past
6 years. METHODS: This study was a retrospective analysis of
the National Ambulatory Medical Care Survey (NAMCS) from
2000–2005. Ischemic stroke related visits in persons aged 45
years were identiﬁed using diagnosis codes (ICD9CM) 433.1x,
434.xx, and 436.xx. Visits per/1000 persons were calculated
using United States population estimates. With logistic regres-
sion, we adjusted associations between stroke-related visits and
physician type (Neurology, Primary Care, and Cardiovascular
Medicine), for age, race, and region (Northeast, Midwest, West,
and South), sex, diabetes, hypertension, insurance type, and
survey year. RESULTS: From 2000 to 2005, stroke related out-
patient physician ofﬁce visits ambulatory care visits increased
signiﬁcantly from 4.7/1000 persons to 6.3/1000 (P
Trend =< 0.0001) persons, a 131% increase. During the study
period, the proportion of ambulatory stroke-related visits that
were to a neurologist increased signiﬁcantly from 15.5% in 2000
to 26.3% in 2005 (P Trend =< 0.0001). However, during the
same period, visits to primary care (2000: 74.4% vs. 2005:
67.8%), and cardiovascular medicine (2000: 10.0% vs. 2005:
5.9%) decreased. After adjustment, greater odds of stroke-
related visits to neurologist (OR = 10.6 95% CI: 7.9–14.1)
whereas no signiﬁcant differences were observed for cardiovas-
cular medicine (OR = 1.5 95% CI: 0.9–2.2) (Reference Category:
Primary Care). CONCLUSION: From 2000 to 2005, stroke-
related ambulatory physician visits increased signiﬁcantly overall
but particularly to neurologists. Secondary stroke prevention,
historically performed by primary care physicians in the US, may
be increasingly performed by neurologists. Given predictions for
large rises in stroke prevalence due to the aging population and
improved stroke survival, US demand for neurologists may be
insufﬁcient.
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OBJECTIVE: Disease state management (DSM) programs are
recommended for patients with conditions such as diabetes,
hypertension, and hyperlipidemia. However, the level of adop-
tion of these programs is not known. The objective of this
study is to determine the level of utilization of DSM programs
in the United States. METHODS: Data from the National
Ambulatory Medical Care Survey (NAMCS), which includes a
nationally representative sample of outpatient physician ofﬁce
visits, was used to meet the study objectives. In year 2005,
NAMCS included an additional item regarding enrollment in
DSM programs. Patients with diabetes, hypertension, or hyper-
lipidemia were identiﬁed and estimates for enrollment in DSM
programs were computed. Logistic regression analysis was used
to identify predictors of enrollment in such programs. Sample
weights and the complex sampling design of the NAMCS were
accounted in all the analyses. RESULTS: The ﬁnal study sample
included 3,884 patient visits. Patients with diabetes had the
highest rate of enrollment (24.6%), followed by patients with
hyperlipidemia (20.4%) and hypertension (19.5%). Insurance
status was an important predictor of enrollment status with
patients enrolled in Medicare [Odds Ratio (OR) = 1.68;
p = 0.021] and Medicaid (OR = 2.13; p = 0.008) signiﬁcantly
more likely to be enrolled in a DSM program as compared to
those without insurance. Patients of Hispanic ethnicity were
67% less likely to be enrolled in a DSM program (OR = 0.33;
p < 0.001). The only co-morbid condition that was a signiﬁcant
predictor of enrollment status was depression. Patients with
co-morbid depression were 1.87 times more likely to be
enrolled as compared to those without depression (OR = 1.87;
p = 0.004). CONCLUSION: Although the beneﬁts of DSM
programs have been documented, their adoption rate remains
extremely low. This study indicates that Hispanic ethnicity,
insurance status and co-morbid depression were predictors of
enrollment status. Additional studies are needed to identify
other predictors and to tailor interventions to increase the
adoption of such programs.
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OBJECTIVE: The primary aim was to determine the impact
on INR control resulting from the integration of information
on patient health literacy and numeracy, health knowledge and
health beliefs regarding warfarin therapy into the clinical infor-
mation provided to the pharmacist. METHODS: A single-
blinded randomized controlled study was conducted to test the
hypothesis that including information on patient’s health lit-
eracy, numeracy, and anticoagulation knowledge and beliefs
improves patient INR control. Patients were recruited from
anticoagulation management services at the University of Mary-
land Medical Center and the Baltimore VA Medical Center.
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